About this trial

To determine the safety and efficacy of Amniotic and Umbilical Cord Tissue for the treatment of the following condition categories: Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions. The hypotheses are that the treatments are not only extremely safe, but also statistically beneficial for all conditions. Outcomes will be determined by numerous valid outcome instruments that compile general quality of life information along with condition-specific information as well.

Eligibility criteria

Qualifiers

Age 18 and over.

Ability to attend follow up visits or at least converse on phone or complete email follow up forms.

Competent to understand the study protocol and provide voluntary informed consent.

Patients with any of the following conditions: Arthritis (Degenerative, Rheumatoid, Psoriatic, Lupus, Gout), Sports or Overuse Injuries (e.g. Rotator Cuff injury, Tennis Elbow), Chronic Kidney Disease (may be on dialysis), Back/Neck Pain, Erectile Dysfunction, Peyronie's Disease, Alzheimer's Disease, Parkinson's Disease, Neuropathy, Post-Stroke, Post-Concussion Syndrome, COPD, Emphysema, Pulmonary Fibrosis, Post myocardial infarction (at least 6 months out), Cardiomyopathy, Congestive Heart Failure.

Disqualifiers

Active Cancer

Pregnancy, Lactating

Severe Clotting disorder

Myocardial Infarction less than six months ago.

Trial design

Treatments tested in this trial

  • Amniotic and Umbilical Cord Tissue Procedure

Treatment groups

5,000 Participants
are divided into 7 treatment groups

7

Treatment groups

See each treatment group below.

Locations

This trial has no locations

Sponsors and collaborators

R3 Stem Cell

Lead sponsor